<code id='6B87838232'></code><style id='6B87838232'></style>
    • <acronym id='6B87838232'></acronym>
      <center id='6B87838232'><center id='6B87838232'><tfoot id='6B87838232'></tfoot></center><abbr id='6B87838232'><dir id='6B87838232'><tfoot id='6B87838232'></tfoot><noframes id='6B87838232'>

    • <optgroup id='6B87838232'><strike id='6B87838232'><sup id='6B87838232'></sup></strike><code id='6B87838232'></code></optgroup>
        1. <b id='6B87838232'><label id='6B87838232'><select id='6B87838232'><dt id='6B87838232'><span id='6B87838232'></span></dt></select></label></b><u id='6B87838232'></u>
          <i id='6B87838232'><strike id='6B87838232'><tt id='6B87838232'><pre id='6B87838232'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:knowledge    Page View:492
          Mayo Clinic, in Rochester, Minnesota on
          Photo by KEREM YUCEL/AFP via Getty Images

          SAN FRANCISCO — Mayo Clinic has signed Silicon Valley tech startup Cerebras as its first generative AI partner, the health system announced Monday.

          The health system — known for its cutting-edge research and willingness to partner with tech companies — will give Cerebras millions of dollars to help build technology tools based on Mayo’s trove of de-identified patient data, leaders announced at the J.P. Morgan Healthcare Conference. Mayo and Cerebras did not disclose the dollar amount, but Cerebras said it was a multimillion, multi-year contract.

          advertisement

          With roughly 380 employees, Cerebras builds and sells supercomputers specifically designed for AI applications across several industries — pitting the upstart in direct competition with the market leader Nvidia Corp. Life sciences giants including GSK have used its technology for drug discovery, and it has partnered with a health network in United Arab Emirates, but this is Cerebras’ first AI contract with a U.S. health system. The deal gives Mayo access to Cerebras’ supercomputers as well as a Cerebras team to help develop health-tuned models; Mayo will then own whatever they build.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          What is STAT's opinion section for?
          What is STAT's opinion section for?

          AdobeThispiecewasadaptedfromarecentFirstOpinionnewsletter.SignuptoreceivetheFirstOpinionnewsletterev

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Obesity experts on risks of Wegovy, Ozempic weight loss drugs

          ObesityexpertsJamyArd(left)andRobertLustigspeakatapanelduringthe2023STATBreakthroughSummit.SarahGonz